DK0613683T4 - Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation - Google Patents

Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation

Info

Publication number
DK0613683T4
DK0613683T4 DK94101461T DK94101461T DK0613683T4 DK 0613683 T4 DK0613683 T4 DK 0613683T4 DK 94101461 T DK94101461 T DK 94101461T DK 94101461 T DK94101461 T DK 94101461T DK 0613683 T4 DK0613683 T4 DK 0613683T4
Authority
DK
Denmark
Prior art keywords
preparation
erythropoietin
inhalation
pulmonary administration
epo
Prior art date
Application number
DK94101461T
Other languages
Danish (da)
English (en)
Other versions
DK0613683T3 (da
Inventor
Colin G Pitt
Robert M Platz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21760356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0613683(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0613683T3 publication Critical patent/DK0613683T3/da
Publication of DK0613683T4 publication Critical patent/DK0613683T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94101461T 1993-02-04 1994-02-02 Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation DK0613683T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/013,514 US5354934A (en) 1993-02-04 1993-02-04 Pulmonary administration of erythropoietin

Publications (2)

Publication Number Publication Date
DK0613683T3 DK0613683T3 (da) 2000-04-03
DK0613683T4 true DK0613683T4 (da) 2003-07-14

Family

ID=21760356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94101461T DK0613683T4 (da) 1993-02-04 1994-02-02 Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation

Country Status (14)

Country Link
US (1) US5354934A (fr)
EP (1) EP0613683B2 (fr)
JP (1) JP4338214B2 (fr)
AT (1) ATE187061T1 (fr)
AU (1) AU677378B2 (fr)
CA (1) CA2155334C (fr)
DE (1) DE69421835T3 (fr)
DK (1) DK0613683T4 (fr)
ES (1) ES2139678T5 (fr)
GR (1) GR3032374T3 (fr)
HK (1) HK1009239A1 (fr)
IL (1) IL108528A (fr)
WO (1) WO1994017784A1 (fr)
ZA (1) ZA94737B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257956B2 (fr) * 1986-08-19 2000-11-22 Genentech, Inc. Usage de facteurs de croissance et de cytocines polypeptides pour fabriquer un dispositif et une dispersion
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
ATE299892T1 (de) 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
CA2216443A1 (fr) * 1995-03-31 1996-10-03 Aradigm Corporation Administration intrapulmonaire d'un medicament hematopoietique
JP3708553B2 (ja) * 1995-04-14 2005-10-19 ネクター セラピューティクス 向上した分散性を有する粉末型薬理組成物
EP2055712A1 (fr) 1995-06-07 2009-05-06 Glaxo Group Limited Peptides et composés se liant à un récepteur de la thrombopoïétine
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
ATE247948T1 (de) * 1996-04-29 2003-09-15 Dura Pharma Inc Verfahren zum inhalieren trockener pulver
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
JP2002512039A (ja) 1998-04-22 2002-04-23 コーネル リサーチ ファンデーション インク. イヌエリスロポエチン遺伝子および組換えタンパク質
MXPA01011429A (es) * 1999-05-11 2003-09-10 Ortho Mcneil Pharm Inc Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina.
US20030190644A1 (en) 1999-10-13 2003-10-09 Andreas Braun Methods for generating databases and databases for identifying polymorphic genetic markers
ATE364689T1 (de) 1999-11-18 2007-07-15 Dendreon Corp Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
SK11142002A3 (sk) * 1999-12-30 2004-09-08 Chiron Corporation Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
ATE420630T1 (de) * 2000-11-29 2009-01-15 Itoham Foods Inc Pulverzubereitungen und verfahren zu ihrer herstellung
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
NZ548578A (en) * 2001-02-02 2008-03-28 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
WO2002072786A2 (fr) 2001-03-13 2002-09-19 Corvas International, Inc. Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
KR20040011480A (ko) 2001-03-22 2004-02-05 덴드레온 샌 디에고 엘엘씨 세린 프로테아제 cvsp14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
ES2268044T3 (es) * 2001-05-21 2007-03-16 Injet Digital Aerosols Limited Composiciones para la administracion de proteinas por la via pulmonar.
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
AU2002351746A1 (en) * 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
AU2003228809A1 (en) 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
MXPA05003057A (es) 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
EP1852441B1 (fr) 2002-09-24 2012-03-28 The Burnham Institute Agents qui modulent l'activité du récepteur EPH
WO2004047768A2 (fr) * 2002-11-26 2004-06-10 Seacoast Neuroscience, Inc. Articles polymeres flottants pour l'administration d'agents therapeutiques au systeme nerveux central
US20040132645A1 (en) * 2003-01-03 2004-07-08 Knox Susan J. Methods for modulating effects of radiation in a subject
WO2004073623A2 (fr) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Traitement d'etats pathologiques associes a la biodisponibilite reduite de l'oxyde nitrique, y compris des etats pathologiques causes par l'activite elevee de l'arginase
CA2521979A1 (fr) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions et procedes associes a la production d'erythropoietine
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
EP1848461A2 (fr) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugues d'une fraction d'epo et d'un polymere
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080210748A1 (en) 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
TW200810773A (en) * 2006-04-19 2008-03-01 Alba Therapeutics Corp Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
KR101476458B1 (ko) 2006-07-05 2015-01-05 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
CA2767773C (fr) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprenant un sel et un agent d'interruption de cristallisation
EP3875104A1 (fr) * 2011-10-17 2021-09-08 Acceleron Pharma Inc. Procédés et compositions pour traiter de la myélofibrose
CA2861392C (fr) 2012-01-26 2021-08-17 Christopher J. Soares Antagonistes peptidiques de la famille calcitonine cgrp d'hormones peptidiques et leur utilisation
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
WO2015136527A1 (fr) 2014-03-10 2015-09-17 Health Corporation - Rambam Peptides inhibiteurs de l'héparanase et leur utilisation pour le traitement de pathologies cliniques
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
ES2965087T3 (es) 2016-09-02 2024-04-10 Soares Christopher J Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
EP3658191A1 (fr) 2017-07-26 2020-06-03 Janssen Pharmaceutica NV Procédés de protection de l'intégrité vasculaire induite par une radiothérapie ciblée
KR20210119469A (ko) 2019-01-25 2021-10-05 잔센파마슈티카엔.브이. 전신 방사선/화학 노출에 대응한 장기 및 혈관 손상에 대한 보호, 조혈 회복 및 생존을 증진시키는 방법
WO2020209920A2 (fr) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Procédés d'atténuation des effets toxiques d'agents vésicants et de gaz caustiques
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
WO2020201038A1 (fr) 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Administration inhalée de mutéines de lipocaline
BR112022001185A2 (pt) 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
WO2021214339A2 (fr) 2020-04-24 2021-10-28 Acm Biolabs Pte Ltd Vaccin contre les coronavirus pathogènes humains
US20230398207A1 (en) 2020-12-11 2023-12-14 Acm Biolabs Pte Ltd Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
AU2022216818A1 (en) 2021-02-02 2023-07-27 Acm Biolabs Pte Ltd Sole use of polymersome associated adjuvant for stimulating an immune response
KR20230165917A (ko) 2021-04-08 2023-12-05 피어이스 파마슈티컬즈 게엠베하 결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production
WO2023168426A1 (fr) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions et cellules contenant des mélanges de protéines de fusion oligo-trap (ofps) et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (de) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultraschall-Nebelerzeugungsgeraet
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
EP0257956B2 (fr) 1986-08-19 2000-11-22 Genentech, Inc. Usage de facteurs de croissance et de cytocines polypeptides pour fabriquer un dispositif et une dispersion
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
KR890006252A (ko) * 1987-10-15 1989-06-12 헤르비그 폰 모르체 분말형 폴리펩타이드의 비강내 투여용 조성물 및 투여방법
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5394866A (en) 1991-03-05 1995-03-07 Aradigm Corporation Automatic aerosol medication delivery system and methods
CA2082951C (fr) * 1991-03-15 1999-12-21 Robert M. Platz Administration au niveau pulmonaire du facteur stimulant la proliferation des granulocytes
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
WO1993013752A1 (fr) 1992-01-21 1993-07-22 Sri International Procede ameliore de preparation de medicaments polypeptides sous forme de poudre
AU660824B2 (en) 1992-06-12 1995-07-06 Teijin Limited Pharmaceutical preparation for intra-airway administration

Also Published As

Publication number Publication date
EP0613683A1 (fr) 1994-09-07
DE69421835T2 (de) 2000-05-18
DK0613683T3 (da) 2000-04-03
AU677378B2 (en) 1997-04-24
EP0613683B1 (fr) 1999-12-01
HK1009239A1 (en) 1999-05-28
DE69421835T3 (de) 2003-12-24
JP4338214B2 (ja) 2009-10-07
ES2139678T3 (es) 2000-02-16
DE69421835D1 (de) 2000-01-05
ATE187061T1 (de) 1999-12-15
US5354934A (en) 1994-10-11
WO1994017784A1 (fr) 1994-08-18
AU6098794A (en) 1994-08-29
CA2155334C (fr) 2006-08-15
IL108528A0 (en) 1994-05-30
IL108528A (en) 1999-05-09
GR3032374T3 (en) 2000-04-27
CA2155334A1 (fr) 1994-08-18
ES2139678T5 (es) 2003-12-01
ZA94737B (en) 1994-09-29
JPH08507753A (ja) 1996-08-20
EP0613683B2 (fr) 2003-06-04

Similar Documents

Publication Publication Date Title
DK0613683T3 (da) Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation
FR2651677B1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
ATE77557T1 (de) Zusammensetzung zur erhoehung der intrazell-atpspiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
IL90435A (en) 4-(quinoline-2-yl-methoxy) phenylacetic acid derivatives, their preparation and pharmaceutical compositions containing them
DE69002718T2 (de) Medikamente.
WO1998009599A3 (fr) Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
PT89802A (pt) Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas
NO924578L (no) Ny taurinbasert farmasoeytisk blanding for administrering ved inhalasjon
ATE32882T1 (de) Phenylnonatetraensaeurederivate, ihre herstellung und pharmazeutische praeparate mit diesen derivaten.
DK144885A (da) Substituerede 4-hydroxybenzopyraner eller farmaceutisk acceptable additionssalte deraf, deres fremstilling og anvendelse som laegemidler
JPS6416890A (en) Antioxidant
DK624186D0 (da) 6h-isoxazolo(5,4-d)pyrazolo(3,4-6)pyridiner eller farmaceutisk acceptable syreadditionssalte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter til fremstillingen
SE8503771L (sv) Nya farmaceutiska preparat
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
DE69121058D1 (de) Salze von Glykosaminoglykanen mit Aminosäureester, ihre Herstellung sowie sie enthaltende pharmazeutische Zusammensetzungen
JPS6456622A (en) Percutaneous absorbefacient base composition
DK568584A (da) Azabicyclo(3,3,1)nonan-9-oner eller stereoisomere eller farmaceutiskacceptable syreadditionssalte deraf, deres fremstilling og anvendelse samt mellemprodukter til fremstillingen
ATE4808T1 (de) Piperidinderivate von 3-hydroxy-thiophen-2carbons[ureestern,ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
St Jean et al. Does absorption mediate hypnotic time perception?
DE3579074D1 (de) Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
IT8422646A0 (it) Contengono. composti derivati dell'acido beta-ossimino-propionico adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li
DE3672635D1 (de) Esterderivate von 2,2-dimethyl-3-ethenylcyclopropancarbonsaeure, ihre herstellung, ihre verwendung als parasitizide und sie enthaltende zusammensetzungen.
LaRue USX Sets Major Divestitures: American Bridge Sold to Its President, Rowley
ATE6655T1 (de) Derivate von adenosin, ihre herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.
IT8520439A0 (it) Preparazione e composizioni derivati del bornano, loro terapeutiche contenenti gli stessi.